Table 2

Treatment-related adverse events

Nivolumab and TACE (N=31)
Grade 1
n (%)
Grade 2
n (%)
Grade 3–4
n (%)
Grade 5
n (%)
Immunotherapy attributed
Dermatological5 (16)2 (6.5)1 (3.2)
Diarrhea/colitis2 (6.5)1 (3.2)
Fatigue4 (13)1 (3.2)
Liver toxicity4 (13)
Thyroid toxicity1 (3.2)3 (9.7)
Polyarthritis1 (3.2)
Pneumonitis
Anorexia/weight loss1 (3.2)2 (6.5)
Fever1 (3.2)1 (3.2)
Pruritus1 (3.2)1 (3.2)
Other toxicities3 (9.7)*2 (6.5)†1 (3.2)‡
TACE attributed
Abdominal pain10 (32)1 (3.2)
Fever2 (6.5)
Fatigue3 (9.7)
Transaminitis1 (3.2)2 (6.5)
Nausea/vomiting2 (6.5)
Nivolumab alone (N=104)
Grade 1
n (%)
Grade 2
n (%)
Grades 3 and 4
n (%)
Grade 5
n (%)
Dermatological15 (14)5 (4.8)2 (1.9)
Diarrhea/colitis4 (3.8)1 (1.0)
Fatigue13 (13)2 (1.9)
Liver toxicity9 (8.7)
Thyroid toxicity4 (3.8)
Polyarthritis1 (1.0)1 (1.0)
Pneumonitis1 (1.0)2 (1.9)
Anorexia/weight loss1 (1.0)1 (1.0)
Fever2 (1.9)
Pruritus
Other toxicities4 (3.8)§3 (2.9)¶1 (1.0)**1 (1.0)††
  • *Balanitis, hair loss, infusion reaction.

  • †Epigastric pain, nephritis.

  • ‡Shortness of breath

  • §Pituitary, double vision, anemia, constipation

  • ¶Hepatic coma, visual changes and constipation

  • **Amylase/lipase

  • ††Myocarditis

  • TACE, transarterial chemoembolization.